Stay updated on Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.2%
    Check dated 2025-06-05T21:07:15.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    4%
    Check dated 2025-05-29T16:06:21.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    29 days ago
    No Change Detected
  5. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.2%
    Check dated 2025-05-01T03:40:10.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    The page has undergone a version update from v2.14.4 to v2.15.0, indicating a significant revision. Additionally, a specific reference to contacting Seattle Genetics' Medical Information has been removed.
    Difference
    3%
    Check dated 2025-04-16T14:26:11.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.2%
    Check dated 2025-04-09T09:18:31.000Z thumbnail image
  8. Check
    108 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    3%
    Check dated 2025-02-24T20:46:02.000Z thumbnail image

Stay in the know with updates to Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.